How to Strengthen Immunity of Patients undergoing HIV AIDS Treatment

Researchers from McGill Univ. Health Center and NIH have collaborated together in a study, the findings of which could shortly pave the way to development of the drug arsenal employed for HIV AIDS treatment.

The VGTI and Université de Montréal study typifies the key function of duo molecules, namely, IL-10 and PD-1, in manoeuvring the task of CD4/T-helper cells and modifying their capability in combating HIV.

Researchers explained how their findings reveal that up-regulation of PD-1 membrane protein occurs all through the HIV infection by discharge of bacterial produce from the stomach which consequently raises the manufacture of IL-10 (cell-derived factor) that cripples the immune system. The scientists believe they are the pioneers in showing that these duo molecules functions in tandem for shutting down the operation of CD4 T-cells among HIV infected people which in turn could bring out breakdown of the immune system and hastened ailment advancement.

Scientists pointed out that their study outcomes indicate that it is crucial that PD-1 as well as IL-10 be blocked for restoring the immune response at the time of HIV infection. They deem that the arsenal employed for restoring immune function in HIV-inflicted individuals should involve immunotherapy targeting IL-10 and PD-10.

About HIV AIDS Treatment

In the past two decades, HIV AIDS treatment has advanced and presently employs HAART highly active antiretroviral therapy. This anti-retroviral treatment comprises of a potent cocktail of a minimal of 3 anti-retroviral drugs that suppresses viral duplication in the blood that has a weakening effect on the immune system. HAART medications that are widely utilized for treating HIV infection comprise of:

• Medications like emtricitabine, abacavir, tenofovir, lamivudine and emtricitabine (Nucleoside reverse transcriptase inhibitors) that are mostly merged with other drugs for deriving more favourable outcomes.
• NNRTI (non-nucleoside reverse transcriptase inhibitors) medicines like nevirapine, etravirine and efavirenz.
• PI (protease inhibitor) like ritonavir, indinavir, tipranavir, saquinavir, ritonavir, nelfinavir or fosamprenavir.
• Medicine raltegravir which is an integrase inhibitor.
• Drugs like maraviroc and enfuvirtide which are fusion and entry inhibitors.

The choice of commencing on HAART prior to health deteriorating is a convoluted one. Prior to HAART treatment being started by the doctor, the likely advantages and risks of early therapy and all pertinent matters must be properly discussed.

Despite, HAART been proven to postpone the advancement of AIDS and prolonging existence, it is not remedial and the pursuit for enhanced therapies carries on.